Table of Content

1. Introduction


2. Research Methodology


3. Executive Summary


4. Market Dynamics

4.1 Growth Drivers
4.2 Challenges
4.3 Opportunities


5. Porter’s Five Forces

5.1 Bargaining Power of Buyers
5.2 Bargaining Power of Suppliers
5.3 Degree of Competition
5.4 Threat of New Entrants
5.5 Threat of Substitutes


6 SWOT Analysis – Multiple Myeloma Market

6.1 Strengths
6.2 Weaknesses
6.3 Opportunities
6.4 Threats


7. Global Multiple Myeloma (MM) - Market & Patient Numbers

7.1 Multiple Myeloma Market
7.2 Multiple Myeloma Patient Population


8. Share Analysis - Global Multiple Myeloma

8.1 By Countries Market Share
8.2 By Treatment Types Market Share
8.3 By Epidemiology Scenario Share
8.4 By Gender Share


9. Multiple Myeloma - Disease Overview

9.1 Introduction
9.2 Symptoms and Diagnosis
9.3 Pathophysiology
9.4 Causes and Risk Factors
9.5 Treatment


10. Multiple Myeloma Patient Journey


11. Multiple Myeloma - Epidemiology and Patient Population

11.1 Epidemiology Scenario - Top 10 Markets

11.1.1 Epidemiology Scenario (2017-2022)
11.1.2 Epidemiology Forecast (2023-2030)

11.2 Epidemiology Scenario - United States

11.2.1 Epidemiology Scenario (2017-2022)
11.2.2 Epidemiology Forecast (2023-2030)

11.3 Epidemiology Scenario - Germany

11.3.1 Epidemiology Scenario (2017-2022)
11.3.2 Epidemiology Forecast (2023-2030)

11.4 Epidemiology Scenario - France

11.4.1 Epidemiology Scenario (2017-2022)
11.4.2 Epidemiology Forecast (2023-2030)

11.5 Epidemiology Scenario - United Kingdom

11.5.1 Epidemiology Scenario (2017-2022)
11.5.2 Epidemiology Forecast (2023-2030)

11.6 Epidemiology Scenario - Italy

11.6.1 Epidemiology Scenario (2017-2022)
11.6.2 Epidemiology Forecast (2023-2030)

11.7 Epidemiology Scenario - Spain

11.7.1 Epidemiology Scenario (2017-2022)
11.7.2 Epidemiology Forecast (2023-2030)

11.8 Epidemiology Scenario - Japan

11.8.1 Epidemiology Scenario (2017-2022)
11.8.2 Epidemiology Forecast (2023-2030)

11.9 Epidemiology Scenario - Australia

11.11.1 Epidemiology Scenario (2017-2022)
11.11.2 Epidemiology Forecast (2023-2030)

11.10 Epidemiology Scenario - China

11.10.1 Epidemiology Scenario (2017-2022)
11.10.2 Epidemiology Forecast (2023-2030)

11.11 Epidemiology Scenario - Saudi Arabia

11.11.1 Epidemiology Scenario (2017-2022)
11.11.2 Epidemiology Forecast (2023-2030)


12. Multiple Myeloma - Epidemiology and Patient Population - By Gender

12.1 Epidemiology Scenario - Top 10 Markets

12.1.1 Epidemiology Scenario Male and Forecast
12.1.2 Epidemiology Scenario Female Forecast

12.2 Epidemiology Scenario - United States

12.2.1 Epidemiology Scenario Male and Forecast
12.2.2 Epidemiology Scenario Female Forecast

12.3 Epidemiology Scenario - Germany

12.3.1 Epidemiology Scenario Male and Forecast
12.3.2 Epidemiology Scenario Female Forecast

12.4 Epidemiology Scenario - France

12.4.1 Epidemiology Scenario Male and Forecast
12.4.2 Epidemiology Scenario Female Forecast

12.5 Epidemiology Scenario - United Kingdom

12.5.1 Epidemiology Scenario Male and Forecast
12.5.2 Epidemiology Scenario Female Forecast

12.6 Epidemiology Scenario - Italy

12.6.1 Epidemiology Scenario Male and Forecast
12.6.2 Epidemiology Scenario Female Forecast

12.7 Epidemiology Scenario - Spain

12.7.1 Epidemiology Scenario Male and Forecast
12.7.2 Epidemiology Scenario Female Forecast

12.8 Epidemiology Scenario - Japan

12.8.1 Epidemiology Scenario Male and Forecast
12.8.2 Epidemiology Scenario Female Forecast

12.9 Epidemiology Scenario - Australia

12.9.1 Epidemiology Scenario Male and Forecast
12.9.2 Epidemiology Scenario Female Forecast

12.10 Epidemiology Scenario - China

12.12.1 Epidemiology Scenario Male and Forecast
12.12.2 Epidemiology Scenario Female Forecast

12.11 Epidemiology Scenario - Saudi Arabia

12.11.1 Epidemiology Scenario Male and Forecast
12.11.2 Epidemiology Scenario Female Forecast


13. Multiple Myeloma - Market Scenario

13.1 Market Scenario - Key Insights
13.2 Market Scenario - Top 10 Markets

13.2.1 Multiple Myeloma - Market Size (2017-2022)
13.2.2 Market Forecast (2023-2030)

13.3 Market Scenario - United States

13.3.1 Multiple Myeloma - Market Size (2017-2022)
13.3.2 Market Size Forecast (2023-2030)
13.3.3 Multiple Myeloma - Access and Reimbursement Overview

13.4 Market Scenario - Germany

13.4.1 Multiple Myeloma - Market Size (2017-2022)
13.4.2 Market Size Forecast (2023-2030)
13.4.3 Multiple Myeloma - Access and Reimbursement Overview

13.5 Market Scenario - France

13.5.1 Multiple Myeloma - Market Size (2017-2022)
13.5.2 Market Size Forecast (2023-2030)
13.5.3 Multiple Myeloma - Access and Reimbursement Overview

13.6 Market Scenario - United Kingdom

13.6.1 Multiple Myeloma - Market Size (2017-2022)
13.6.2 Market Size Forecast (2023-2030)
13.6.3 Multiple Myeloma - Access and Reimbursement Overview

13.7 Market Scenario - Italy

13.7.1 Multiple Myeloma - Market Size (2017-2022)
13.7.2 Market Size Forecast (2023-2030)
13.7.3 Multiple Myeloma - Access and Reimbursement Overview

13.8 Market Scenario - Spain

13.8.1 Multiple Myeloma - Market Size (2017-2022)
13.8.2 Market Size Forecast (2023-2030)
13.8.3 Multiple Myeloma - Access and Reimbursement Overview

13.9 Market Scenario - Japan

13.9.1 Multiple Myeloma - Market Size (2017-2022)
13.9.2 Market Size Forecast (2023-2030)
13.9.3 Multiple Myeloma - Access and Reimbursement Overview

13.10 Market Scenario - Australia

13.10.1 Multiple Myeloma - Market Size (2017-2022)
13.10.2 Market Size Forecast (2023-2030)
13.10.3 Multiple Myeloma - Access and Reimbursement Overview

13.11 Market Scenario - China

13.13.1 Multiple Myeloma - Market Size (2017-2022)
13.13.2 Market Size Forecast (2023-2030)
13.13.3 Multiple Myeloma - Access and Reimbursement Overview

13.12 Market Scenario - Saudi Arabia

13.12.1 Multiple Myeloma - Market Size (2017-2022)
13.12.2 Market Size Forecast (2023-2030)
13.12.3 Multiple Myeloma - Access and Reimbursement Overview

14. Multiple Myeloma - Treatment Algorithm, Guidelines, and Medical Practices

14.1 Guidelines, Management and Treatment
14.2 Treatment Algorithm

15. Multiple Myeloma Unmet Needs

16. Multiple Myeloma - Key Endpoints of Treatment

16.1 Targeted Therapy
16.2 Chemotherapy
16.3 Others

17. Multiple Myeloma - Marketed Products

17.1 List of Multiple Myeloma Marketed Drugs across the Top 10 Markets

17.1.1 Xpovio (Selinexor) - Karyopharm

17.1.1.1 Drug Overview
17.1.1.2 Mechanism of Action
17.1.1.3 Regulatory Status
17.1.1.4 Clinical Trial Results
17.1.1.5 Sales Across Major Markets

17.1.2 Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical

17.1.2.1 Drug Overview
17.1.2.2 Mechanism of Action
17.1.2.3 Regulatory Status
17.1.2.4 Clinical Trial Results
17.1.2.5 Sales Across Major Markets

17.1.3 Proteasome inhibitor (Kyprolis)- Amgen / Ono (Japan)

17.1.3.1 Drug Overview
17.1.3.2 Mechanism of Action
17.1.3.3 Regulatory Status
17.1.3.4 Clinical Trial Results
17.1.3.5 Sales Across Major Markets

17.1.4 HDAC inhibitor (Farydak) - Novartis

17.1.4.1 Drug Overview
17.1.4.2 Mechanism of Action
17.1.4.3 Regulatory Status
17.1.4.4 Clinical Trial Results
17.1.4.5 Sales Across Major Markets

17.1.5 Sarclisa (Isatuximab) - Sanofi

17.1.5.1 Drug Overview
17.1.5.2 Mechanism of Action
17.1.5.3 Regulatory Status
17.1.5.4 Clinical Trial Results
17.1.5.5 Sales Across Major Markets

18. Multiple Myeloma - Pipeline Drugs

18.1 List of Multiple Myeloma Pipeline Drugs across the Top 10 Markets

18.1.1 Encorafenib - Array BioPharma/Ono Pharmaceutical/Pierre Fabre

18.1.1.1 Drug Overview
18.1.1.2 Mechanism of Action
18.1.1.3 Clinical Trial Results
18.1.1.4 Safety and Efficacy
18.1.1.5 Regulatory Status

18.1.2 Elranatamab - Pfizer

18.1.2.1 Drug Overview
18.1.2.2 Mechanism of Action
18.1.2.3 Clinical Trial Results
18.1.2.4 Safety and Efficacy
18.1.2.5 Regulatory Status

18.1.3 Alnuctamab - Celgene, Bristol-Myers Squibb

18.1.3.1 Drug Overview
18.1.3.2 Mechanism of Action
18.1.3.3 Clinical Trial Results
18.1.3.4 Safety and Efficacy
18.1.3.5 Regulatory Status

18.1.4 CAR-T ddBCMA - Gilead Sciences

18.1.4.1 Drug Overview
18.1.4.2 Mechanism of Action
18.1.4.3 Clinical Trial Results
18.1.4.4 Safety and Efficacy
18.1.4.5 Regulatory Status

18.1.5 Masitinib - AB Science

18.1.5.1 Drug Overview
18.1.5.2 Mechanism of Action
18.1.5.3 Clinical Trial Results
18.1.5.4 Safety and Efficacy
18.1.5.5 Regulatory Status

18.1.6 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals

18.1.6.1 Drug Overview
18.1.6.2 Mechanism of Action
18.1.6.3 Clinical Trial Results
18.1.6.4 Safety and Efficacy
18.1.6.5 Regulatory Status


19. Company Analysis

19.1 Sanofi (France)

19.1.1 Overview
19.1.2 Recent Developments
19.1.3 Financial Analysis

19.2 Pfizer Inc. (US)

19.2.1 Overview
19.2.2 Recent Developments
19.2.3 Financial Analysis

19.3 GlaxoSmithKline plc (UK)

19.3.1 Overview
19.3.2 Recent Developments
19.3.3 Financial Analysis

19.4 Novartis AG (Switzerland)

19.4.1 Overview
19.4.2 Recent Developments
19.4.3 Financial Analysis

19.5 Bayer AG (Germany)

19.5.1 Overview
19.5.2 Recent Developments
19.5.3 Financial Analysis

19.6 Eli Lilly and Company (US)

19.6.1 Overview
19.6.2 Recent Developments
19.6.3 Financial Analysis

19.7 Merck & Co., Inc. (US)

19.7.1 Overview
19.7.2 Recent Developments
19.7.3 Financial Analysis

19.8 AstraZeneca

19.8.1 Overview
19.8.2 Recent Developments
19.8.3 Financial Analysis



List of Figures

Figure-01: Global – Multiple Myeloma (MM) Market (Billion US$), 2017 – 2022
Figure-02: Global – Forecast for Multiple Myeloma (MM) Market (Billion US$), 2023 – 2030
Figure-03: Global – Multiple Myeloma (MM) Patient Population (Thousand), 2017 – 2022
Figure-04: Global – Forecast for Multiple Myeloma (MM) Patient Population (THousand), 2023 – 2030
Figure-05: Top 10 Countries – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-06: Top 10 Countries – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-07: United States – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-08: United States – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-09: Germany – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-10: Germany – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-11: France – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-12: France – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-13: United Kingdom – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-14: United Kingdom – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-15: Italy – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-16: Italy – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-17: Spain – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-18: Spain – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-19: Japan – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-20: Japan – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-21: Australia – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-22: Australia – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-23: China – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-24: China – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-25: Saudi Arabia – Epidemiology Scenario Patient Population (Number), 2017 – 2022
Figure-26: Saudi Arabia – Forecast for Epidemiology Scenario Patient Population (Number), 2023 – 2030
Figure-27: Top 10 Countries – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-28: Top 10 Countries – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-29: Top 10 Countries – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-30: Top 10 Countries – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-31: United States – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-32: United States – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-33: United States – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-34: United States – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-35: Germany – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-36: Germany – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-37: Germany – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-38: Germany – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-39: France – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-40: France – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-41: France – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-42: France – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-43: United Kingdom – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-44: United Kingdom – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-45: United Kingdom – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-46: United Kingdom – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-47: Italy – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-48: Italy – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-49: Italy – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-50: Italy – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-51: Spain – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-52: Spain – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-53: Spain – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-54: Spain – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-55: Japan – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-56: Japan – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-57: Japan – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-58: Japan – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-59: Australia – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-60: Australia – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-61: Australia – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-62: Australia – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-63: China – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-64: China – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-65: China – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-66: China – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-67: Saudi Arabia – Epidemiology Scenario Male Patient Population (Number), 2017 – 2022
Figure-68: Saudi Arabia – Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 – 2030
Figure-69: Saudi Arabia – Epidemiology Scenario Female Patient Population (Number), 2017 – 2022
Figure-70: Saudi Arabia – Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 – 2030
Figure-71: Top 10 Countries – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-72: Top 10 Countries – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-73: United States – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-74: United States – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-75: Germany – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-76: Germany – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-77: France – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-78: France – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-79: United Kingdom – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-80: United Kingdom – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-81: Italy – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-82: Italy – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-83: Spain – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-84: Spain – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-85: Japan – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-86: Japan – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-87: Australia – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-88: Australia – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-89: China – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-90: China – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-91: Saudi Arabia – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-92: Saudi Arabia – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-93: Targeted Therapy – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-94: Targeted Therapy – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-95: Chemotherapy – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-96: Chemotherapy – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-97: Others – Multiple Myeloma (MM) Market (Million US$), 2017 – 2022
Figure-98: Others – Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 – 2030
Figure-99: Xpovio (Selinexor) - Karyopharm – Market (Million US$), 2018 – 2022
Figure-100: Xpovio (Selinexor) - Karyopharm – Forecast for Market (Million US$), 2023 – 2030
Figure-101: Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical – Market (Million US$), 2018 – 2022
Figure-102: Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical – Forecast for Market (Million US$), 2023 – 2030
Figure-103: Proteasome inhibitor (Kyprolis)- Amgen / Ono (Japan) – Market (Million US$), 2018 – 2022
Figure-104: Proteasome inhibitor (Kyprolis)- Amgen / Ono (Japan) – Forecast for Market (Million US$), 2023 – 2030
Figure-105: HDAC inhibitor (Farydak) - Novartis – Market (Million US$), 2018 – 2022
Figure-106: HDAC inhibitor (Farydak) - Novartis – Forecast for Market (Million US$), 2023 – 2030
Figure-107: Sarclisa (Isatuximab) - Sanofi – Market (Million US$), 2020 – 2022
Figure-108: Sarclisa (Isatuximab) - Sanofi – Forecast for Market (Million US$), 2023 – 2030
Figure-109: Sanofi – Global Revenue Market (Billion US$), 2018 – 2022
Figure-110: Sanofi – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-111: Pfizer Inc. – Global Revenue Market (Billion US$), 2018 – 2022
Figure-112: Pfizer Inc. – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-113: GlaxoSmithKline plc – Global Revenue Market (Billion US$), 2018 – 2022
Figure-114: GlaxoSmithKline plc – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-115: Novartis AG – Global Revenue Market (Billion US$), 2018 – 2022
Figure-116: Novartis AG – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-117: Bayer AG – Global Revenue Market (Billion US$), 2018 – 2022
Figure-118: Bayer AG – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-119: Eli Lilly and Company – Global Revenue Market (Billion US$), 2018 – 2022
Figure-120: Eli Lilly and Company – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-121: Merck & Co., Inc. – Global Revenue Market (Billion US$), 2018 – 2022
Figure-122: Merck & Co., Inc. – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-123: AstraZeneca – Global Revenue Market (Billion US$), 2018 – 2022
Figure-124: AstraZeneca – Forecast for Global Revenue Market (Billion US$), 2023 – 2030

List of Tables

Table-01: Global – Multiple Myeloma (MM) Market Share by Countries (Percent), 2018 – 2022
Table-02: Global – Forecast for Multiple Myeloma (MM) Market Share by Countries (Percent), 2023 – 2030
Table-03: Global – Multiple Myeloma (MM) Market Share by Treatment Type (Percent), 2018 – 2022
Table-04: Global – Forecast for Multiple Myeloma (MM) Market Share by Treatment Type (Percent), 2023 – 2030
Table-05: Global – Multiple Myeloma (MM) Volume Share by Epidemiology Scenario (Percent), 2018 – 2022
Table-06: Global – Forecast for Multiple Myeloma (MM) Volume Share by Epidemiology Scenario (Percent), 2023 – 2030
Table-07: Global – Multiple Myeloma (MM) Market Share by Gender (Percent), 2018 – 2022
Table-08: Global – Forecast for Multiple Myeloma (MM) Market Share by Gender (Percent), 2023 – 2030